• LAST PRICE
    13.9600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.0000/ 0
  • Ask / Lots
    14.6800/ 70
  • Open / Previous Close
    14.1300 / 13.9600
  • Day Range
    Low 13.8000
    High 14.3100
  • 52 Week Range
    Low 9.2600
    High 19.9700
  • Volume
    221,225
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 14.36
TimeVolumeACRS
09:32 ET241914.23
09:34 ET30014.31
09:41 ET80014.2
09:43 ET22714.2
09:45 ET110014.235
09:52 ET20014.175
09:57 ET10014.07
10:01 ET10014.06
10:03 ET77514.06
10:10 ET10013.98
10:12 ET10013.96
10:14 ET20013.93
10:15 ET81513.98
10:21 ET10013.94
10:24 ET30014
10:28 ET20014.09
10:30 ET20014.08
10:33 ET10014.12
10:35 ET10014.15
10:39 ET30014.14
10:42 ET40014.12
10:44 ET49714.12
10:50 ET10014.12
10:53 ET277914.04
10:55 ET10014.04
11:00 ET10014.025
11:02 ET152014.03
11:04 ET160013.95
11:06 ET20014.02
11:09 ET120014
11:11 ET40013.96
11:13 ET60013.99
11:18 ET20014
11:24 ET10014.03
11:26 ET90014
11:29 ET10013.98
11:31 ET100013.935
11:33 ET20013.935
11:36 ET88313.92
11:40 ET10013.93
11:44 ET10113.945
11:45 ET50014
11:49 ET20014.02
11:51 ET20014.02
11:58 ET50014
12:00 ET10014.02
12:05 ET17114.015
12:07 ET48214
12:09 ET10014
12:12 ET30013.99
12:16 ET20014.005
12:18 ET20013.99
12:20 ET97814.03
12:21 ET10014.05
12:23 ET30014.08
12:27 ET40014.09
12:32 ET10014.13
12:38 ET30014.1
12:39 ET10014.14
12:43 ET10014.14
12:50 ET20014.1
12:52 ET50014.1
01:01 ET10014.06
01:03 ET90014.12
01:08 ET40014.08
01:12 ET10014.05
01:15 ET50013.995
01:21 ET100014.01
01:24 ET30013.95
01:26 ET50013.94
01:30 ET30013.91
01:32 ET30013.88
01:33 ET170013.845
01:37 ET90013.84
01:42 ET113813.84
01:46 ET50013.8
01:48 ET60013.85
01:50 ET10013.86
01:53 ET10913.935
01:55 ET82813.95
01:57 ET46313.95
02:00 ET90013.92
02:04 ET30013.9
02:06 ET10013.89
02:09 ET10013.9
02:13 ET84513.945
02:15 ET30013.97
02:20 ET100014.02
02:22 ET40014.01
02:24 ET10014.01
02:26 ET118113.98
02:27 ET120014.04
02:29 ET50014.05
02:31 ET60014.08
02:33 ET90014.09
02:36 ET40014.095
02:40 ET10014.08
02:42 ET90014.04
02:44 ET30014.03
02:45 ET80014.01
02:47 ET121814.07
02:49 ET10014.08
02:51 ET61114.06
02:54 ET10014.045
02:56 ET10014.02
02:58 ET11114.025
03:02 ET20014.01
03:05 ET80014.03
03:07 ET20014.02
03:09 ET60014.02
03:12 ET90014.02
03:16 ET40013.99
03:18 ET10013.965
03:21 ET10013.95
03:27 ET53313.93
03:30 ET70013.905
03:32 ET60013.93
03:34 ET150013.95
03:36 ET70013.95
03:38 ET137314.035
03:39 ET160014.036
03:41 ET130013.98
03:43 ET131513.94
03:45 ET70013.95
03:48 ET126913.97
03:50 ET150013.91
03:52 ET261313.95
03:54 ET164213.88
03:56 ET284313.87
03:57 ET482613.89
03:59 ET433713.96
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesACRS
Aclaris Therapeutics Inc
929.5M
-10.3x
---
United StatesRCKT
Rocket Pharmaceuticals Inc
905.9M
-5.1x
---
United StatesBLU
BELLUS Health Inc
981.5M
-11.1x
---
United StatesCRNX
Crinetics Pharmaceuticals Inc
997.9M
-6.6x
---
United StatesREPL
Replimune Group Inc
857.7M
-7.7x
---
United StatesMORF
Morphic Holding Inc
830.4M
-7.5x
---
As of 2022-07-01

Company Information

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing drug candidates for immuno-inflammatory diseases. The Company is focused on leveraging its experience in drug discovery and development and kinase inhibition to develop small molecule therapies to help people impacted immuno-inflammatory conditions. The Company’s drug candidates are Zunsemetinib (ATI-450), ATI-1777 and ATI-2138. The Company’s ATI-450, an investigational oral, small molecule selective MK2 inhibitor compound, for the treatment of rheumatoid arthritis. Its ATI-1777, an investigational topical soft-JAK 1/3 inhibitor compound, for the treatment of atopic dermatitis. The Company is engaged in developing ATI-2138, its investigational oral inhibitor compound, as a potential treatment for T-cell mediated autoimmune diseases. It is also developing oral gut biased JAK inhibitors, as a potential treatment for inflammatory bowel disease.

Contact Information

Headquarters
SUITE 400, 101 LINDENWOOD DRIVEMALVERN, PA, United States 19355
Phone
484-321-5554
Fax
302-655-5049

Executives

Independent Chairman of the Board
Christopher Molineaux
President, Chief Executive Officer, Co-Founder, Director
Neal Walker
Co-Founder, Chief Financial Officer, Secretary
Frank Ruffo
Chief Scientific Officer
Joseph Monahan
Chief Medical Officer
Gail Cawkwell

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$929.5M
Revenue (TTM)
$6.4M
Shares Outstanding
66.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.62
EPS
$-1.36
Book Value
$3.22
P/E Ratio
-10.3x
Price/Sales (TTM)
144.4
Price/Cash Flow (TTM)
---
Operating Margin
-1,244.38%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.